CN102770450B - 因子viii融合蛋白 - Google Patents

因子viii融合蛋白 Download PDF

Info

Publication number
CN102770450B
CN102770450B CN201180009864.4A CN201180009864A CN102770450B CN 102770450 B CN102770450 B CN 102770450B CN 201180009864 A CN201180009864 A CN 201180009864A CN 102770450 B CN102770450 B CN 102770450B
Authority
CN
China
Prior art keywords
molecule
fviii
fusion
domain
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180009864.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102770450A (zh
Inventor
G.博尔特
K.克杰加尔德
P.L.诺尔比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201510524808.4A priority Critical patent/CN105153313A/zh
Publication of CN102770450A publication Critical patent/CN102770450A/zh
Application granted granted Critical
Publication of CN102770450B publication Critical patent/CN102770450B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180009864.4A 2010-02-16 2011-02-10 因子viii融合蛋白 Expired - Fee Related CN102770450B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510524808.4A CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153715 2010-02-16
EP10153715.7 2010-02-16
US30617710P 2010-02-19 2010-02-19
US61/306177 2010-02-19
PCT/EP2011/051959 WO2011101284A1 (en) 2010-02-16 2011-02-10 Factor viii fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510524808.4A Division CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Publications (2)

Publication Number Publication Date
CN102770450A CN102770450A (zh) 2012-11-07
CN102770450B true CN102770450B (zh) 2015-12-02

Family

ID=42244627

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180009864.4A Expired - Fee Related CN102770450B (zh) 2010-02-16 2011-02-10 因子viii融合蛋白
CN201510524808.4A Withdrawn CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510524808.4A Withdrawn CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Country Status (5)

Country Link
US (2) US9493543B2 (cg-RX-API-DMAC7.html)
EP (2) EP2977055A1 (cg-RX-API-DMAC7.html)
JP (3) JP2013519699A (cg-RX-API-DMAC7.html)
CN (2) CN102770450B (cg-RX-API-DMAC7.html)
WO (1) WO2011101284A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
EP2804623B1 (en) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
EP2814840B1 (en) 2012-02-15 2019-11-13 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
CN104411716B (zh) * 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
EP2841091A1 (en) 2012-04-24 2015-03-04 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
SG10201701037WA (en) 2012-07-11 2017-03-30 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
EP2989122B1 (en) 2013-04-23 2019-04-03 President and Fellows of Harvard College Genetic reprogramming of bacterial biofilms
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
LT3041513T (lt) 2013-09-08 2020-11-25 Kodiak Sciences Inc. Viii faktoriaus cviterioninių polimerų konjugatai
HRP20220960T1 (hr) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Kimerni proteini faktora viii i njihova upotreba
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
DK3177317T3 (en) 2014-08-04 2020-06-15 Csl Ltd Factor viii formulation
JP6849590B2 (ja) * 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
AU2016231327B2 (en) 2015-03-06 2018-08-09 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
EP3280397A4 (en) * 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
WO2016198521A1 (en) * 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
KR20180031775A (ko) 2015-08-12 2018-03-28 셀 머신스, 인크. 긴 반감기 응집 복합체와 관련된 방법 및 조성물
GB201520021D0 (en) * 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017201428A1 (en) 2016-05-19 2017-11-23 President And Fellows Of Harvard College Methods of making gels and film using curli nanofibers
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
CN108623695B (zh) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
WO2019219048A1 (zh) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 具有延长半衰期的融合多肽缀合物
US12440572B2 (en) * 2018-05-18 2025-10-14 Zhengzhou Gensciences Inc. FVIII fusion protein and use thereof
CN110950964B (zh) * 2018-09-26 2021-06-18 安源医药科技（上海）有限公司 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
JP7780341B2 (ja) 2019-07-04 2025-12-04 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
CA3150442A1 (en) * 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
JP7462762B2 (ja) * 2020-01-20 2024-04-05 ウーシー バイオロジクス アイルランド リミテッド アフィニティークロマトグラフィー用の新規な洗浄緩衝液
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
BR112023005257A2 (pt) * 2020-09-23 2023-04-25 Ablevia Biotech Gmbh Composto para a prevenção ou tratamento de condições mediadas por autoanticorpos
KR20250013211A (ko) * 2022-05-25 2025-01-31 지앙수 젠사이언시스 아이엔씨. 연장된 반감기를 갖는 fviii 융합 단백질 접합체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317641B1 (en) 1987-05-29 1993-03-17 Sagami Chemical Research Center Fused protein containing lymphotoxin
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US6939677B1 (en) 1990-11-01 2005-09-06 Cancer Research Fund Of Contra Costa Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6524572B1 (en) 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
DK2322229T3 (en) 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and Glycoconjugation of Factor IX
EP2272533A1 (en) 2003-01-13 2011-01-12 MacroGenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2005040382A2 (de) 2003-10-28 2005-05-06 Alexander Cherkasky Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende
US20070275873A1 (en) 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
AU2006226782B2 (en) 2005-03-24 2011-12-08 Ratiopharm Gmbh Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1980615A4 (en) 2006-01-31 2010-04-21 Ishihara Sangyo Kaisha POLYPEPTIDE WITH AFFINITY FOR A CURVED VIRUS COMPONENT AND USE THEREOF IN THE TRANSFER OF A SUBSTANCE INTO A CELL
EP2059527B1 (en) * 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
US20080219978A1 (en) * 2007-01-23 2008-09-11 Ellsworth Jeff L Soluble FcgammaRIA and related methods
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
ES2476690T3 (es) * 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
CN103739712B (zh) * 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Factor VIII-Fc Fusion Protein Shows Extended Half-Life and Hemostatic Activity in Hemophilia A Dogs;Jennifer A Dumon et al;《BLOOD》;20091130;第114卷(第22期);摘要 *

Also Published As

Publication number Publication date
US20170015729A1 (en) 2017-01-19
EP2977055A1 (en) 2016-01-27
JP2016084365A (ja) 2016-05-19
US20130040889A1 (en) 2013-02-14
EP2536754A1 (en) 2012-12-26
CN105153313A (zh) 2015-12-16
WO2011101284A1 (en) 2011-08-25
CN102770450A (zh) 2012-11-07
JP2017190342A (ja) 2017-10-19
JP6185097B2 (ja) 2017-08-23
JP2013519699A (ja) 2013-05-30
US9493543B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
CN102770450B (zh) 因子viii融合蛋白
US11472863B2 (en) Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof
KR102276157B1 (ko) 고글리코실화 인간 혈액응고인자 viii 융합 단백질 및 그 제조방법과 용도
CN102770449B (zh) 具有降低的vwf结合的因子viii分子
CN103739712B (zh) 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
US20160264645A1 (en) Stabilized Factor VIII Variants
CN112673026B (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
CN106279436B (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
HK40051475A (en) Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151202

Termination date: 20180210